The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...
Annual Recurring Revenue was $603.1M, up 17.7% year-over-year. “Vertex’s (VERX) 2024 financial results demonstrated the power of our business and financial model, which is built to deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results